Home LiteratureArticle Details
PMID: 3812484 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.

American journal of human genetics ·Vol. 40 ·No. 1 ·1987-01-00 ·Pages 15-31

Fabbro D, Desnick RJ, Grabowski GA

Abstract

The genetic heterogeneity of Gaucher disease subtypes and variants was investigated by immunoblotting of fibroblast extracts. For these studies polyclonal and monoclonal antibodies were raised to acid beta-glucosidase preparations containing a single N-terminal amino acid sequence that was colinear with that encoded by the beta-Glc cDNAs. Three forms (Mr approximately equal to 67,000, 64,000-61,000, and 58,000) of cross-reacting immunologic material (CRIM) were observed in control individuals. Decreased amounts of the same CRIM forms were detected in most type 1 Gaucher disease patients, but single CRIM forms of variable molecular weight were observed in several non-Jewish type 1 variants. One or two CRIM forms of variable molecular weight were found in neuronopathic (type 2 and type 3) patients. The amount of CRIM was severely decreased in the majority of the type 2 and type 3 patients; one American black type 2 patient was CRIM negative. With this one exception, one CRIM form was detected in the cell-free culture media from all normal or Gaucher disease fibroblasts that had an Mr approximately 2,000 greater than the highest respective intracellular molecular-weight form. All intra- or extracellular CRIM forms were reduced to a single form after deglycosylation with N-Glycanase. In addition, the radioactivity from [3H]Br-conduritol B epoxide, a specific covalent inhibitor of beta-Glc, localized to the CRIM forms of beta-Glc on immunoblots. These results indicate that all subtypes and variants of Gaucher disease result from mutations that alter the stability and/or processing of beta-Glc. Furthermore, the heterogeneity of the CRIM patterns within and among the variants of Gaucher disease cause the diagnostic usefulness of immunoblotting to be restricted to those families in which the phenotype has been well established.

MeSH Terms
Antibodies, Monoclonal Cells, Cultured Fibroblasts/enzymology Gaucher Disease/enzymology,genetics Genetic Variation Glucosidases/analysis Glucosylceramidase/analysis,deficiency,immunology Humans Molecular Weight Phenotype Solubility
Chemicals
Antibodies, Monoclonal Glucosidases Glucosylceramidase
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Fabbro D
Desnick R J
Grabowski G A
References (29)
29 references, click to expand
  1. Gaucher disease: the effects of phosphatidylserine on glucocerebrosidase from normal and Gaucher fibroblasts.
    Hum Genet. 1984;67(4):432-6 PMID: 6436168
  2. A case of juvenile Gaucher's disease with intraneuronal lipid storage.
    J Neurol Neurosurg Psychiatry. 1960 Aug;23:207-13 PMID: 14420412
  3. Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.
    Am J Hum Genet. 1985 May;37(3):499-510 PMID: 4003396
  4. Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.
    Am J Med Genet. 1985 Jul;21(3):529-49 PMID: 3927728
  5. Biosynthesis of the lysosomal enzyme glucocerebrosidase.
    J Biol Chem. 1985 Nov 15;260(26):14319-24 PMID: 3932353
  6. Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA.
    Proc Natl Acad Sci U S A. 1985 Nov;82(21):7289-93 PMID: 3864160
  7. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  8. Molecular basis for the alpha1-protease inhibitor deficiency.
    Nature. 1975 May 15;255(5505):240-1 PMID: 1079921
  9. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
    Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 PMID: 388439
  10. Non-neuropathic Gaucher disease presenting in infancy.
    Arch Dis Child. 1979 Sep;54(9):707-9 PMID: 518109
  11. Gaucher disease--Norrbottnian type. I. General clinical description.
    Eur J Pediatr. 1980 Mar;133(2):107-18 PMID: 7363908
  12. beta-Glucosidase assays in the diagnosis of Gaucher's disease.
    Clin Chem. 1982 Apr;28(4 Pt 1):569-77 PMID: 6804115
  13. Pathology of the Gaucher cell.
    Prog Clin Biol Res. 1982;95:151-75 PMID: 7122633
  14. Homozygote and heterozygote identification.
    Prog Clin Biol Res. 1982;95:551-72 PMID: 6812086
  15. Enzymic differentiation of neurologic and nonneurologic forms of Gaucher's disease.
    J Neuropathol Exp Neurol. 1982 Nov;41(6):630-41 PMID: 6813430
  16. Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease.
    Proc Natl Acad Sci U S A. 1982 Sep;79(18):5607-10 PMID: 6957882
  17. Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease.
    Am J Hum Genet. 1983 Jul;35(4):621-8 PMID: 6881138
  18. Determination of Gaucher's disease phenotypes with monoclonal antibody.
    Clin Chim Acta. 1983 Jul 15;131(3):283-7 PMID: 6883722
  19. Human lysosomal beta-glucosidase: kinetic characterization of the catalytic, aglycon, and hydrophobic binding sites.
    Arch Biochem Biophys. 1984 May 15;231(1):144-57 PMID: 6426391
  20. Molecular weight characterization of beta-D-glucocerebrosidase in mononuclear white blood cells in Gaucher's disease.
    Biochem Med. 1984 Feb;31(1):73-9 PMID: 6743300
  21. Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase F.
    Biochemistry. 1985 Aug 13;24(17):4665-71 PMID: 4063349
  22. Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase.
    J Biol Chem. 1986 Jan 5;261(1):50-3 PMID: 3001061
  23. Human acid beta-glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes.
    J Biol Chem. 1986 Jun 25;261(18):8263-9 PMID: 3087971
  24. Human acid beta-glucosidase: affinity purification of the normal placental and Gaucher disease splenic enzymes on N-alkyl-deoxynojirimycin-sepharose.
    Enzyme. 1986;35(3):147-53 PMID: 2944742
  25. Protein measurement with the Folin phenol reagent.
    J Biol Chem. 1951 Nov;193(1):265-75 PMID: 14907713
  26. Gaucher's disease in 29 cases: hematologic complications and effect of splenectomy.
    Ann Intern Med. 1954 Mar;40(3):481-92 PMID: 13139127
  27. Gaucher's disease without splenomegaly. Oldest patient on record, with review.
    N Y State J Med. 1962 Jul 15;62:2346-54 PMID: 13873139
  28. METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.
    Biochem Biophys Res Commun. 1965 Jan 18;18:221-5 PMID: 14282020
  29. Cross-reacting material in Gaucher disease fibroblasts.
    Proc Natl Acad Sci U S A. 1984 Oct;81(20):6506-10 PMID: 6593712
Article Info
Journal
American journal of human genetics
Abbr.
Am J Hum Genet
ISSN
0002-9297
Published
1987-01-00
Pages
15-31
Language
English
Region
United States
NLM ID
0370475
PMCID
PMC1684010
Subset
IM
Grants
NIDDK NIH HHS · K04 DK01351 · United States
NIDDK NIH HHS · R01-DK 36729 · United States
NCRR NIH HHS · RR-71 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com